文献速递类风湿关节炎

自身抗体标志物与RA一线治疗反应:CAP48队列发现

Autoantibody biomarkers and first-line therapy response in RA: findings from the CAP48 cohort.
PubMed 文献 · RMD Open · 2026-03-13

在CAP48早期未治疗RA观察队列165份基线样本中,用ELISA检测抗UH-RA.305/318/329抗体。该抗体阳性与部分临床指标下未达缓解或低疾病活动度相关:全队列9个月、血清阴性患者6个月与24个月均见关联。

要点

  • 抗UH-RA.305/318/329抗体阳性与一线治疗未达LDA相关,全队列见于9个月。
  • 血清阴性RA中该抗体与未达LDA的关联在6个月和24个月均显著。
  • 该抗体panel需进一步验证后方可用于早期RA个体化治疗。

核心结论

  • 在CAP48队列中,抗UH-RA.305/318/329抗体panel与一线治疗反应不佳相关,全队列见于9个月,血清阴性患者见于6个月和24个月。

研究设计与样本

  • 观察性队列CAP48的165份基线样本,患者为早期未治疗RA,主要接受甲氨蝶呤单药治疗;ELISA检测抗UH-RA.305/318/329抗体反应性,多变量分析评估其与3、6、9、24个月未达缓解或LDA的关联。

主要发现

  • 全RA队列中,9个月未达LDA者基线抗体反应性显著高于达LDA者(DAS28CRP/SDAI为31.6% vs 11.3%;OR 3.64,95%CI 1.34至9.91,p=0.045)。
  • 血清阴性RA患者中,6个月未达DAS28CRP定义的LDA与抗体反应性显著相关(42.1% vs 12.5%;OR 5.09,95%CI 1.2至27.0,p=0.05)。
  • 24个月时,血清阴性患者基线抗体阳性仍与未达SDAI定义的LDA显著相关(OR 29.9,95%CI 2.5至109.2,p=0.01)。

关键数值与推荐

  • 全队列9个月未达LDA:抗体反应性31.6% vs 11.3%,OR 3.64(95%CI 1.34至9.91),p=0.045。
  • 血清阴性RA 6个月未达DAS28CRP-LDA:42.1% vs 12.5%,OR 5.09(95%CI 1.2至27.0),p=0.05。
  • 血清阴性RA 24个月未达SDAI-LDA:OR 29.9(95%CI 2.5至109.2),p=0.01。

临床怎么用

  • 在早期未治疗RA中,可考虑检测抗UH-RA.305/318/329抗体以辅助识别一线治疗反应不佳风险较高的患者,尤其血清阴性者;但原文强调需进一步验证后方可用于个体化治疗。

局限性

  • 原文为观察性队列,样本量165份基线样本;抗体panel的临床效用尚需独立验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A panel of antibodies against three antigens, University Hasselt (UH)-rheumatoid arthritis (RA).305, 318 and 329, has been associated with lack of response to first-line therapy in the Care in early RA trial. This study aimed to determine the association of this antibody panel with first-line therapy response in an independent cohort. METHODS: Anti-UH-RA.305/318/329 antibody reactivity was determined using ELISA in 165 baseline samples of the CAP48 cohort, an observational cohort of patients with early and naïve RA treated mainly with methotrexate monotherapy. Multivariable analyses assessed associations between baseline antibody reactivity and failure to reach remission or low disease activity (LDA) at 3, 6, 9 and 24 months according to the Disease Activity Score 28-joint C-reactive protein (DAS28CRP) and clinical/simplified disease activity index (SDAI). RESULTS: In the total RA cohort, baseline anti-UH-RA.305/318/329 antibody reactivity was significantly higher in patients not achieving LDA versus those achieving LDA at 9 months (31.6% vs 11.3% for DAS28CRP/SDAI; OR 3.64, 95% CI 1.34 to 9.91, p=0.045). In patients with seronegative RA, a significant association between antibody reactivity and not achieving LDA based on DAS28CRP (42.1% vs 12.5%; OR 5.09, 95% CI 1.2 to 27.0, p=0.05) was already observed at 6 months. After 24 months, baseline antibody positivity remained significantly associated with not achieving LDA based on SDAI (OR 29.9, 95% CI 2.5 to 109.2, p=0.01) in patients with seronegative status. DISCUSSION: In the CAP48 cohort, the anti-UH-RA antibody panel was associated with a lack of response to first-line therapy for certain clinical measures, observed at 9 months in the total RA cohort and at 6 and 24 months in patients with seronegative status. The antibody panel should be further validated for its use in early personalised RA treatment.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Fadlallah S, Fraussen J, Ruytinx P, et al. Autoantibody biomarkers and first-line therapy response in RA: findings from the CAP48 cohort. RMD Open. 2026. PMID: 41825926. doi:10.1136/rmdopen-2025-006407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。